Welcome to our dedicated page for MINIMED GROUP SEC filings (Ticker: MMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MINIMED GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MINIMED GROUP's regulatory disclosures and financial reporting.
MiniMed Group, Inc. reported that officer Dianaty Ali received multiple grants of common stock on March 11, 2026, all with a grant price of $0.00 per share. These are classified as awards rather than open-market purchases.
The grants represent MMED restricted stock units created when prior Medtronic restricted and performance share awards were converted following MiniMed’s separation from Medtronic effective March 9, 2026, under an Employee Matters Agreement. The MMED RSUs were issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest on several dates between July 31, 2026 and October 29, 2028, including single-date vesting and a three-installment schedule.
MiniMed Group, Inc. EVP and Chief Financial Officer Chad Spooner received multiple equity awards in connection with MiniMed’s separation from Medtronic plc. On March 11, 2026, he was granted time-vesting restricted stock units (MMED RSUs) that were created by converting prior Medtronic restricted stock and performance share awards under an Employee Matters Agreement tied to the March 9, 2026 separation.
The grants cover 70,896 shares vesting on April 28, 2028, 127,609 shares vesting in three equal installments on July 28, 2026, July 28, 2027 and July 28, 2028, and 70,896 shares vesting on July 28, 2028. All awards were issued at a reported price of $0.00 per share as compensation, not as open-market purchases or sales, and were made under the 2026 MiniMed Group, Inc. Long Term Incentive Plan.
MiniMed Group, Inc. reported that Chief Executive Officer Dallara Que received multiple equity awards in the form of MiniMed common stock–denominated restricted stock units on March 11, 2026. These awards were granted at a price of $0.00 per share as compensation, not through open-market purchases.
The footnotes explain that existing Medtronic restricted stock units and performance share units held by Que were converted into MiniMed RSUs in connection with MiniMed’s separation from Medtronic plc, under an Employee Matters Agreement. The converted RSUs were issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest on various dates between July 31, 2026 and April 28, 2028, with one grant vesting in two installments on March 10, 2026 and March 10, 2027.
MiniMed Group, Inc. director Timothy A. Wicks reported an acquisition of 13,889 shares of common stock through a grant of restricted stock units. These units vest on the one-year anniversary of the grant date rather than being immediately transferable.
After this award, Wicks is shown as directly holding 13,889 shares, which include shares to be issued upon the future vesting of one or more restricted stock units. The transaction reflects equity-based compensation rather than an open-market purchase.
MiniMed Group, Inc. director D Keith Grossman reported an equity compensation grant of 13,889 shares of Common Stock on March 9, 2026. The award consists of restricted stock units that vest on the one-year anniversary of the grant date and were granted at no cash cost to him.
Following this grant, Grossman holds 13,889 shares of Common Stock directly, including shares that will be issued upon vesting of one or more restricted stock units. This filing reflects a compensation-related acquisition rather than an open-market stock purchase.
EISENBERG GLENN A reported acquisition or exercise transactions in this Form 4 filing.
MiniMed Group, Inc. director Glenn A. Eisenberg received an equity grant of 13,889 shares of common stock in the form of restricted stock units. The units were awarded at no cash cost and vest on the one-year anniversary of the grant date. Following this award, he directly holds 13,889 shares and units, including shares to be issued upon future vesting of restricted stock units.
MiniMed Group, Inc. director Kevin E. Lofton reported an equity compensation grant of 27,778 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and is scheduled to vest on the one-year anniversary of the grant date.
After this grant, Lofton is shown as owning 27,778 shares directly, which include shares to be issued upon future vesting of one or more restricted stock units. This filing reflects a routine compensation-related acquisition rather than an open-market purchase or sale.
MiniMed Group, Inc. officer John Gyurci reported equity compensation grants on March 9, 2026. He received 2,778 performance-based restricted stock units, each tied to one share of common stock, which vest on March 9, 2027 only if MMED’s closing price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement. He was also granted options on 25,253 shares of common stock at an exercise price of $18.00 per share, expiring on March 9, 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.
MiniMed Group, Inc. officer Chandrasena Gillian reported compensation-related equity awards, not open-market trades. She received 6,945 performance-based restricted stock units, each representing a right to one MMED common share, which vest on March 9, 2027 if MMED’s closing share price is at least $32.05 as of the defined Divestment Date.
She also received employee stock options for 63,132 MMED common shares at an exercise price of $18.00 per share, expiring in 2036. These options vest 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030. All holdings reported are owned directly.
MiniMed Group, Inc. insider Courtney Nelson received new equity awards as compensation. On March 9, 2026, Nelson was granted 6,945 performance-based restricted stock units, each tied to one share of MMED common stock. These units vest on March 9, 2027 if MMED’s closing share price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement.
On the same date, Nelson also received an option to purchase 63,132 shares of MMED common stock at an exercise price of $18.00 per share, expiring March 9, 2036. This option vests 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030. All awards are reported as directly owned and are grants, not open-market purchases or sales.